University of Pittsburgh, Abbott Labs to Develop Ras Inhibitors

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD

June 9th 2025

FDA Approves Mitomycin Solution in Low-Grade Intermediate-Risk NMIBC

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Data from the phase 3 ENVISION trial support the FDA approval of the mitomycin solution for patients with recurrent, low-grade, intermediate-risk NMIBC.

Russ Conroy

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Data from the phase 3 ENVISION trial support the FDA approval of the mitomycin solution for patients with recurrent, low-grade, intermediate-risk NMIBC.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD

June 5th 2025

Adverse Sexual Health Outcomes Appear More Likely in Women With CRC

Experts weigh in on the practical applications of PSMA PET imaging

In patients 39 years and younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.

Roman Fabbricatore

Encorafenib Combo May Limit Recurrence Risk in BRAF V600+ Melanoma

In patients 39 years or younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.

Phase 3 data demonstrate the potential utility of BRAF/MEK inhibition in the adjuvant setting for patients with stage IIB/IIC BRAF V600–mutant melanoma.

Ashley Chan

TPS 38 ELCIN: Elacestrant in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer: An Open-Label, Multicenter, Phase 2 Study

Phase 3 data demonstrate the potential utility of BRAF/MEK inhibition in the adjuvant setting for patients with stage IIB/IIC BRAF V600–mutant melanoma.

Related Content

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD

June 9th 2025

FDA Approves Mitomycin Solution in Low-Grade Intermediate-Risk NMIBC

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Russ Conroy

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Data from the phase 3 ENVISION trial support the FDA approval of the mitomycin solution for patients with recurrent, low-grade, intermediate-risk NMIBC.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD

June 5th 2025

Adverse Sexual Health Outcomes Appear More Likely in Women With CRC

Experts weigh in on the practical applications of PSMA PET imaging

Roman Fabbricatore

Encorafenib Combo May Limit Recurrence Risk in BRAF V600+ Melanoma

In patients 39 years or younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.

Ashley Chan